TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01577849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: administration of Vitamin D3 24,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R206
Description: administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
Study: NCT01217385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DOSI
Description: Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
Study: NCT02584894

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS 1Hz
Description: trauma exposure + repeated transcranial magnetic stimulation at 1Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS 10Hz
Description: trauma exposure + repeated transcranial magnetic stimulation at 10Hz

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoneurological assessment
Description: psychoneurological assessment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: psychoneurological assessment
Description: psychoneurological assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conductivity meter
Description: electrodermal conductance measure

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conductivity meter
Description: electrodermal conductance measure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrocardiogram
Description: heart rate measure

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electrocardiogram
Description: heart rate measure
Study: NCT02611505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
Study: NCT00535847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2a
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2a
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2a
Description: Solution for Injection
Study: NCT03817411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telatinib
Description: 300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
Study: NCT02205905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C PER977
Description: Open-label, single dose
Study: NCT01253174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)
Description: single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)
Description: single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-5-MTHF Ca 0.451 mg (Metafolin)
Description: single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
Study: NCT04157127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.
Study: NCT03706859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet inflation pressure
Description: Pneumatic tourniquet inflation pressure estimation using two different mathematical equations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic tourniquet inflation pressure
Description: Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
Study: NCT00665587

Intervention type: PROCEDURE
Intervention: Cox-MAZE III
Description: Maze procedure according to standards of the department
Study: NCT03475199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FabLife
Description: * A personnalized dietary program depending on the patient's phenotype and genotype~* The daily intake of a dietary supplement, developped in the context of male infertility.
Study: NCT01424046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin glargine
Description: Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
Study: NCT01815606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy with 19 gauge needle
Description: biopsy with 19 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy with 25 gauge needle
Description: biopsy with 25 gauge needle
Study: NCT03813186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 + Day 2 Food
Description: ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 + Day 4 Food
Description: ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
Study: NCT01765244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anterior lamellar nanostructured artificial human cornea.
Description: Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane transplantation
Description: Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
Study: NCT01021761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac
Description: drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Study: NCT02381301

Intervention type: BIOLOGICAL
Intervention: Venous blood sampling prior to CCTA.
Study: NCT05102825

Intervention type: DIAGNOSTIC_TEST
Intervention: 1H and Xe-129 MRI
Description: Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).

Intervention type: DIAGNOSTIC_TEST
Intervention: 1H and Xe-129 MRI
Description: Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
Study: NCT04395092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K-NK002
Description: K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HaploBMT
Description: Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
Study: NCT01576276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Integrated MR-PET scan
Description: Integrated MR-PET scan using \[11C\]diprenorphine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Integrated MR-PET scan
Description: Integrated MR-PET scan using \[11C\]diprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 3 administrations of ketorolac over course of study
Study: NCT02349464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized Preterm Infant/Mother Dyad Lactation Support
Description: Mother will receive home equipment and pediatric clinic lactation support.
Study: NCT01044342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsule; single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsule, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: capsule, single oral dose
Study: NCT02395640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50mg/m2 ivgtt d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 po d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 po d1-14
Study: NCT04342741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter cervical ripening
Description: Participants were assessed when labour was established or the following morning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter cervical ripening
Description: Participants were assessed when labour was established or the following morning.
Study: NCT03578458

Intervention type: OTHER
Group type: OTHER
Intervention: subjects will install a mobile app for use
Description: novel mobile application

Intervention type: OTHER
Group type: OTHER
Intervention: subjects will install a mobile app for use
Description: novel mobile application

Intervention type: OTHER
Group type: OTHER
Intervention: subjects will install a mobile app for use
Description: novel mobile application
Study: NCT03367052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two level Prodisc-C vivo
Description: Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid
Description: The hybrid method will be used in one group of patients.
Study: NCT01048112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campylobacter jejuni strain CG8421
Description: Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Campylobacter jejuni strain CG8421
Description: Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
Study: NCT03273465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Fecal transplantation administered orally via frozen capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal transplantation
Description: Fecal transplantation administered orally via frozen capsules.
Study: NCT03667872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral implantation of DBS system to Habeluna
Description: Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
Study: NCT03627377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Description: Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
Study: NCT03356119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid device
Description: The contraceptive implants of the subjects in this arm are removed by the new IMD.
Study: NCT02021136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebel Reliever
Description: Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual antalgic treatment + physical exercises recommendations
Study: NCT04331067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Given standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: -Given standard of care

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: -Given standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Given standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Given standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: -Will be provided by Bristol Myers Squibb

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor biopsy
Description: -Baseline, week 5, surgery, and at time of relapse (optional)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Baseline, week 5, surgery, and at time of relapse (optional)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Baseline, week 5, surgery, and at time of relapse (optional)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow
Description: -Time of port placement (baseline), time of surgery, and time of recurrence (optional)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow
Description: -Time of port placement (baseline), time of surgery, and time of recurrence (optional)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow
Description: -Time of port placement (baseline), time of surgery, and time of recurrence (optional)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: -Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: -Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: -Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
Study: NCT02542241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride [3%]
Description: Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Study: NCT01044342

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, single oral dose
Study: NCT02817620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulysat®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02493218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Instruction
Description: Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
Study: NCT02542241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride [0.9%]
Description: Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Study: NCT01004224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study: NCT03180658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GTR + CGF + bone graft
Description: Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CGF + bone graft
Description: CGF combined with bone graft to treat mandibular furcation involvements
Study: NCT02351193

Intervention type: OTHER
Intervention: transvaginal Ultrasound

Intervention type: OTHER
Intervention: transvaginal Ultrasound
Study: NCT06369519

Intervention type: PROCEDURE
Intervention: Surgery treatment or local tumor destruction.
Description: Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.

Intervention type: PROCEDURE
Intervention: Surgery treatment or local tumor destruction.
Description: Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.
Study: NCT03048123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion
Description: A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: oxaliplatin,leucovorin and 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE Drug Protocol
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Study: NCT04958148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt pills
Description: Subjects will supplement salt pills with meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Subjects will supplement placebo pills with meals.
Study: NCT02434172

Intervention type: OTHER
Intervention: Pre-emptive screening and treatment for cryptococcal disease
Description: Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.